Evommune, Inc.
EVMN
$24.09
-$0.94-3.76%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -57.14% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -57.14% | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -57.14% | |
| SG&A Expenses | 157.05% | 14.28% | 7.88% | 30.74% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 38.51% | 41.24% | -18.72% | 67.68% | |
| Operating Income | -38.51% | 19.31% | 18.72% | -300.43% | |
| Income Before Tax | -36.41% | 21.62% | 50.46% | -422.88% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -36.41% | 21.62% | 50.46% | -422.88% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -36.41% | 21.62% | 50.46% | -422.88% | |
| EBIT | -38.51% | 19.31% | 18.72% | -300.43% | |
| EBITDA | -39.33% | 19.58% | 19.11% | -320.76% | |
| EPS Basic | 90.17% | 22.85% | 51.33% | -400.85% | |
| Normalized Basic EPS | 89.46% | 22.85% | 51.33% | -400.83% | |
| EPS Diluted | 90.17% | 22.85% | 51.33% | -400.85% | |
| Normalized Diluted EPS | 89.46% | 22.85% | 51.33% | -400.83% | |
| Average Basic Shares Outstanding | 1,194.06% | 1.59% | 1.78% | 4.40% | |
| Average Diluted Shares Outstanding | 1,194.06% | 1.59% | 1.78% | 4.40% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |